DK1212095T3 - Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse - Google Patents

Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse

Info

Publication number
DK1212095T3
DK1212095T3 DK00951802T DK00951802T DK1212095T3 DK 1212095 T3 DK1212095 T3 DK 1212095T3 DK 00951802 T DK00951802 T DK 00951802T DK 00951802 T DK00951802 T DK 00951802T DK 1212095 T3 DK1212095 T3 DK 1212095T3
Authority
DK
Denmark
Prior art keywords
sustained release
release formulation
preparing sustained
preparing
formulation
Prior art date
Application number
DK00951802T
Other languages
Danish (da)
English (en)
Inventor
Thomas Ciaran Loughman
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of DK1212095T3 publication Critical patent/DK1212095T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)
DK00951802T 1999-08-18 2000-08-14 Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse DK1212095T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation
PCT/IE2000/000099 WO2001012232A2 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
DK1212095T3 true DK1212095T3 (da) 2003-10-06

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00951802T DK1212095T3 (da) 1999-08-18 2000-08-14 Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse

Country Status (26)

Country Link
US (1) US6893645B1 (de)
EP (1) EP1212095B1 (de)
JP (1) JP3730917B2 (de)
CN (2) CN1823736A (de)
AR (1) AR022647A1 (de)
AT (1) ATE243044T1 (de)
AU (1) AU755229B2 (de)
BR (1) BR0013349A (de)
CA (1) CA2380902C (de)
CZ (1) CZ294433B6 (de)
DE (1) DE60003438T2 (de)
DK (1) DK1212095T3 (de)
ES (1) ES2195925T3 (de)
HK (1) HK1044285A1 (de)
HU (1) HUP0202895A3 (de)
IE (1) IES990700A2 (de)
IL (1) IL148044A0 (de)
MX (1) MXPA02001415A (de)
NO (1) NO20020762L (de)
NZ (1) NZ517251A (de)
PL (1) PL199862B1 (de)
PT (1) PT1212095E (de)
RU (1) RU2211694C1 (de)
TW (1) TWI230069B (de)
WO (1) WO2001012232A2 (de)
ZA (1) ZA200202027B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348444B1 (de) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
CN1164334C (zh) * 1999-08-18 2004-09-01 研究及应用科学协会股份有限公司 肽的缓释制剂
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
CA2584221A1 (en) 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
PT678018E (pt) * 1993-01-06 2003-08-29 Kinerton Ltd Conjugados moleculares ionicos de poliesteres biodegradaveis e de polipeptidos bioactivos
CA2168113C (en) * 1993-08-09 2002-10-01 Sun Hyuk Kim Therapeutic peptide derivatives
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
WO1999038535A1 (en) 1998-01-29 1999-08-05 Kinerton Limited Process for making absorbable microparticles
WO2000012232A1 (fr) 1998-08-28 2000-03-09 Mitutoyo Corporation Laveuse automatique de pieces pour intervention prealable dans un systeme de mesure et de production automatique equipe de ladite laveuse
CN1164334C (zh) 1999-08-18 2004-09-01 研究及应用科学协会股份有限公司 肽的缓释制剂

Also Published As

Publication number Publication date
MXPA02001415A (es) 2002-08-12
HK1044285A1 (en) 2002-10-18
CN1823736A (zh) 2006-08-30
WO2001012232A8 (en) 2002-06-06
DE60003438T2 (de) 2004-05-06
RU2211694C1 (ru) 2003-09-10
NO20020762D0 (no) 2002-02-15
CA2380902A1 (en) 2001-02-22
HUP0202895A2 (hu) 2003-02-28
CZ2002266A3 (cs) 2002-05-15
EP1212095A2 (de) 2002-06-12
NZ517251A (en) 2003-08-29
BR0013349A (pt) 2002-04-23
WO2001012232A2 (en) 2001-02-22
IES990700A2 (en) 2001-08-22
RU2002106809A (ru) 2004-01-20
PL354263A1 (en) 2003-12-29
JP2003507346A (ja) 2003-02-25
TWI230069B (en) 2005-04-01
DE60003438D1 (de) 2003-07-24
CN1246040C (zh) 2006-03-22
AR022647A1 (es) 2002-09-04
ES2195925T3 (es) 2003-12-16
US6893645B1 (en) 2005-05-17
CZ294433B6 (cs) 2005-01-12
PL199862B1 (pl) 2008-11-28
CN1377283A (zh) 2002-10-30
AU755229B2 (en) 2002-12-05
IL148044A0 (en) 2002-09-12
WO2001012232A3 (en) 2002-04-04
ZA200202027B (en) 2002-12-24
AU6464700A (en) 2001-03-13
EP1212095B1 (de) 2003-06-18
JP3730917B2 (ja) 2006-01-05
HUP0202895A3 (en) 2003-11-28
NO20020762L (no) 2002-04-16
ATE243044T1 (de) 2003-07-15
CA2380902C (en) 2008-08-05
PT1212095E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
NO20021540D0 (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
DE60038784D1 (de) Schnellkupplung
DK1317181T3 (da) Fremgangsmåde til fremstilling af en herbicid faststofformulering
DK1173431T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1326585T3 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1163207T3 (da) Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DK1150966T3 (da) Fremgangsmåde til fremstilling af 5-cyanophthalid
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1272489T3 (da) Fremgangsmåde til præparation af cabergolins krystallinske form I
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1158963T3 (da) Sammensætninger af betahistin med kontrolleret frigivelse
DK1165503T3 (da) Fremgangsmåde til fremstilling af hydroxymethylthiosmörsyreesthere
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1212095T3 (da) Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse
DK1228056T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1232328T3 (da) Fremgangsmåde til indvinding af vandopløselige overfladeaktive midler
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin